Stock data
| Market cap. | C$45.6m |
| Last close | C$0.11 |
| High / Low (52 weeks) | C$0.2 / C$0.1 |
| Stock market listing | TSX |
| Forecast net debt (C$m) | 4.1 |
| Forecast gearing ratio (%) | 185 |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (20.69) | 0 | (17.86) |
| Relative * | (22.6) | (2.73) | (9.4) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (C$m) | EBITDA (C$m) | PBT (C$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2009A | 13.6 | (6.3) | (8.9) | (2.9) | N/A | N/A |
| 2010A | 11.4 | (8.4) | (10.4) | (3.2) | N/A | N/A |
| 2011E | 18.7 | 0.2 | (0.9) | (0.6) | N/A | N/A |
| 2012E | 26.3 | 2.1 | 1.5 | 0.2 | 55.0 | 13.9 |
Last updated on 03/02/2012
Latest research
Revenue receipts roll in
Update | Pharmaceutical & Healthcare | 03/02/2012
A more promising H2
Update | Pharmaceutical & Healthcare | 09/12/2011
A bigger share of the pie
Outlook | Pharmaceutical & Healthcare | 28/06/2011
Debt terms revised
Update | Pharmaceutical & Healthcare | 03/02/2011
China deal secured
Update | Pharmaceutical & Healthcare | 20/10/2010
'Business as usual'
Update | Pharmaceutical & Healthcare | 17/08/2010
Moving on up
Outlook | Pharmaceutical & Healthcare | 05/05/2010
Investment summary
Confirmation of near-term purchase orders and service revenues from key customers means that ProMetic Life Sciences has improved visibility on near-term revenue predictability. The company is now emerging from a period where there was a gap in major orders, and expects 2012 to be a stronger year for revenues. This view is supported by the trigger of a $1m upfront payment related to the $2.5m H112 purchase order under its Octapharma supply agreement, and also the achievement of a key milestone with an undisclosed multinational company, leading to confirmed service revenues in 2012 and a potential long-term resin supply agreement.
Last updated on 03/02/2012
Industry outlook
Other catalysts with the potential to boost revenues and sentiment include progress with product development partnerships, European commercialisation of the P-Capt prion reduction filter, and securing its funding base.
Last updated on 09/12/2011
Key management
| Kym Anthony, Chairman |
| Pierre Laurin, CEO |
| Bruce Pritchard, FD |
Company address
| 531 Boulevarde des Prairies, Bldg. 15 Laval, Québec H7V 1B7 Canada +1 450 781 0115 View website |
